Forum Financial Management LP Acquires 59 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Forum Financial Management LP lifted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 7.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 817 shares of the biopharmaceutical company’s stock after acquiring an additional 59 shares during the period. Forum Financial Management LP’s holdings in Regeneron Pharmaceuticals were worth $570,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Glassman Wealth Services lifted its stake in Regeneron Pharmaceuticals by 19.5% in the first quarter. Glassman Wealth Services now owns 92 shares of the biopharmaceutical company’s stock worth $64,000 after purchasing an additional 15 shares during the last quarter. Minot Wealth Management LLC lifted its stake in Regeneron Pharmaceuticals by 3.8% in the first quarter. Minot Wealth Management LLC now owns 408 shares of the biopharmaceutical company’s stock worth $285,000 after purchasing an additional 15 shares during the last quarter. Stratos Wealth Partners LTD. lifted its stake in Regeneron Pharmaceuticals by 3.1% in the first quarter. Stratos Wealth Partners LTD. now owns 535 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 16 shares during the last quarter. Plancorp LLC lifted its stake in Regeneron Pharmaceuticals by 0.8% in the first quarter. Plancorp LLC now owns 2,276 shares of the biopharmaceutical company’s stock worth $1,590,000 after purchasing an additional 17 shares during the last quarter. Finally, IHT Wealth Management LLC lifted its stake in Regeneron Pharmaceuticals by 5.1% in the fourth quarter. IHT Wealth Management LLC now owns 392 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 19 shares during the last quarter. Institutional investors own 84.92% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the firm’s stock in a transaction that occurred on Friday, July 1st. The shares were sold at an average price of $587.76, for a total value of $646,536.00. Following the completion of the sale, the executive vice president now directly owns 19,644 shares in the company, valued at $11,545,957.44. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, July 1st. The shares were sold at an average price of $587.76, for a total transaction of $646,536.00. Following the completion of the sale, the executive vice president now directly owns 19,644 shares in the company, valued at $11,545,957.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 10,453 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $621.29, for a total transaction of $6,494,344.37. Following the sale, the director now owns 18,408 shares of the company’s stock, valued at $11,436,706.32. The disclosure for this sale can be found here. Insiders sold a total of 52,044 shares of company stock worth $32,114,573 over the last three months. Corporate insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $710.74 on Tuesday. The firm has a market cap of $77.48 billion, a price-to-earnings ratio of 14.19, a PEG ratio of 2.52 and a beta of 0.29. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $754.67. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $607.57 and its 200 day moving average is $636.33.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing the consensus estimate of $9.94 by ($0.17). The firm had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. Regeneron Pharmaceuticals’s revenue was down 44.4% on a year-over-year basis. During the same quarter last year, the business earned $27.97 earnings per share. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.97 EPS for the current fiscal year.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Truist Financial raised their price objective on shares of Regeneron Pharmaceuticals from $718.00 to $790.00 in a research note on Friday. Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “hold” rating and raised their target price for the stock from $536.00 to $675.00 in a research report on Thursday, September 8th. Evercore ISI set a $635.00 target price on shares of Regeneron Pharmaceuticals in a research report on Monday, June 20th. Guggenheim raised their target price on shares of Regeneron Pharmaceuticals from $740.00 to $925.00 in a research report on Monday. Finally, Wells Fargo & Company raised their target price on shares of Regeneron Pharmaceuticals from $735.00 to $800.00 and gave the stock an “overweight” rating in a research report on Monday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $741.58.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.